Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith W Pratz

Showing results (11-20 of 73) with videos related to

Pageof 8
Sort By:
Journal of Hematology & Oncology|March 25, 2023
Recent advances in targeted therapies in acute myeloid leukemiaRahul S Bhansali, Keith W Pratz, Catherine Lai
Cancers|December 11, 2022
Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid LeukemiaAndrew H Matthews, Keith W Pratz, Martin P Carroll
Medicine|July 17, 2007
Intestinal lymphangiectasia with protein-losing enteropathy in Waldenstrom macroglobulinemiaKeith W Pratz, David Dingli, Thomas C Smyrk, et al.
Mayo Clinic Proceedings|January 26, 2005
Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndromeKeith W Pratz, Cynthia Ma, Marie-Christine Aubry, et al.
Blood|December 17, 2009
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AMLKeith W Pratz, Takashi Sato, Kathleen M Murphy, et al.
Investigational New Drugs|November 18, 2011
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patientsMaria Cristina Villarroel, Keith W Pratz, Linping Xu, et al.
American Journal of Hematology|November 16, 2017
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemiaJessica K Altman, James M Foran, Keith W Pratz, et al.
Pharmacoeconomics|June 13, 2022
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer PerspectiveKeith W Pratz, Xinglei Chai, Jipan Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2019
<i>BRCA1</i> Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated <i>miR-155</i> to Disrupt Myeloid Differentiation in Myeloid MalignanciesWeijie Poh, Robert L Dilley, Alison R Moliterno, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 22, 2014
Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemiaMichael R Grunwald, Li-Hui Tseng, Ming-Tseh Lin, et al.
Pageof 8

Showing results (11-20 of 73) with videos related to

Sort By:
Pageof 8
Journal of Hematology & Oncology|March 25, 2023
Recent advances in targeted therapies in acute myeloid leukemiaRahul S Bhansali, Keith W Pratz, Catherine Lai
Cancers|December 11, 2022
Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid LeukemiaAndrew H Matthews, Keith W Pratz, Martin P Carroll
Medicine|July 17, 2007
Intestinal lymphangiectasia with protein-losing enteropathy in Waldenstrom macroglobulinemiaKeith W Pratz, David Dingli, Thomas C Smyrk, et al.
Mayo Clinic Proceedings|January 26, 2005
Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndromeKeith W Pratz, Cynthia Ma, Marie-Christine Aubry, et al.
Blood|December 17, 2009
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AMLKeith W Pratz, Takashi Sato, Kathleen M Murphy, et al.
Investigational New Drugs|November 18, 2011
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patientsMaria Cristina Villarroel, Keith W Pratz, Linping Xu, et al.
American Journal of Hematology|November 16, 2017
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemiaJessica K Altman, James M Foran, Keith W Pratz, et al.
Pharmacoeconomics|June 13, 2022
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer PerspectiveKeith W Pratz, Xinglei Chai, Jipan Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2019
<i>BRCA1</i> Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated <i>miR-155</i> to Disrupt Myeloid Differentiation in Myeloid MalignanciesWeijie Poh, Robert L Dilley, Alison R Moliterno, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 22, 2014
Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemiaMichael R Grunwald, Li-Hui Tseng, Ming-Tseh Lin, et al.
Pageof 8